JP2023539626A5 - - Google Patents
Info
- Publication number
- JP2023539626A5 JP2023539626A5 JP2023513706A JP2023513706A JP2023539626A5 JP 2023539626 A5 JP2023539626 A5 JP 2023539626A5 JP 2023513706 A JP2023513706 A JP 2023513706A JP 2023513706 A JP2023513706 A JP 2023513706A JP 2023539626 A5 JP2023539626 A5 JP 2023539626A5
- Authority
- JP
- Japan
- Prior art keywords
- mmp
- immune cells
- nucleic acid
- pharmaceutical composition
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072046P | 2020-08-28 | 2020-08-28 | |
| US63/072,046 | 2020-08-28 | ||
| PCT/US2021/047889 WO2022047119A1 (en) | 2020-08-28 | 2021-08-27 | Modified immune cells for fibrosis and inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539626A JP2023539626A (ja) | 2023-09-15 |
| JP2023539626A5 true JP2023539626A5 (cg-RX-API-DMAC7.html) | 2024-09-04 |
Family
ID=80354009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513706A Pending JP2023539626A (ja) | 2020-08-28 | 2021-08-27 | 線維症及び炎症のための修飾免疫細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230321144A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4204555A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023539626A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230090314A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116075589A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021331368A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192646A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300671A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002411A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022047119A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250075643A (ko) | 2022-09-27 | 2025-05-28 | 레졸루션 쎄라퓨틱스 리미티드 | 치료용 대식세포 |
| CN115786270A (zh) * | 2022-12-01 | 2023-03-14 | 鲲石生物科技(深圳)有限公司 | 工程化的巨噬细胞及其在治疗纤维化疾病中的应用 |
| CN115590880A (zh) * | 2022-12-01 | 2023-01-13 | 鲲石生物科技(深圳)有限公司(Cn) | 工程化的巨噬细胞联用在治疗纤维化疾病中的应用 |
| CN116699116A (zh) * | 2023-06-14 | 2023-09-05 | 河南省人民医院 | 检测嗜碱性粒细胞cd284表达水平的物质的应用 |
| CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | LDNs在坏死性小肠结肠炎诊断中的应用 |
| CN122270550A (zh) | 2023-09-27 | 2026-06-23 | 分解治疗有限公司 | 治疗性巨噬细胞 |
| WO2025189163A2 (en) * | 2024-03-08 | 2025-09-12 | Carisma Therapeutics Inc. | Modified immune cells for fibrosis and inflammation |
| WO2025202287A1 (en) | 2024-03-26 | 2025-10-02 | Resolution Therapeutics Limited | Method of producing macrophages |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2183752T3 (es) * | 1999-09-17 | 2005-07-16 | Tgt Laboratories, S.A. De C.V. | Vectores adenovirales recombinantes y su utilizacion en el tratamiento de la cirrosis de higado. |
| AU2003224950B2 (en) * | 2002-04-09 | 2006-09-14 | Biogen Ma Inc. | Methods for treating tweak-related conditions |
| EP2549986B1 (en) * | 2010-03-24 | 2019-10-30 | Northeastern University | Multi-compartmental macrophage delivery |
| EP3299453B1 (en) * | 2016-09-23 | 2019-05-08 | Xcell Medical Solutions, S.L. | Cell therapy with polarized macrophages for tissue regeneration |
| US20210100837A1 (en) * | 2017-12-14 | 2021-04-08 | The University Of Chicago | Treatment of fibrosis with genetically-engineered macrophages |
| WO2019238022A1 (en) * | 2018-06-11 | 2019-12-19 | Chineo Medical Technology Co., Ltd. | Modified immune cells and uses thereof |
| WO2020160217A1 (en) * | 2019-02-01 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Microenvironment sensors to regulate engineered gene expression |
| CN111544585B (zh) * | 2019-02-11 | 2024-12-27 | 北京卡替医疗技术有限公司 | 一种可助推免疫细胞在体内扩增的佐剂 |
| US20250051749A1 (en) * | 2021-12-24 | 2025-02-13 | Toolgen Incorporated | Novel promoter and use thereof |
| CN120035671A (zh) * | 2023-05-11 | 2025-05-23 | 四川至善唯新生物科技有限公司 | 工程化的肝脏特异性核心启动子及其应用 |
-
2021
- 2021-08-27 KR KR1020237010233A patent/KR20230090314A/ko active Pending
- 2021-08-27 JP JP2023513706A patent/JP2023539626A/ja active Pending
- 2021-08-27 MX MX2023002411A patent/MX2023002411A/es unknown
- 2021-08-27 CA CA3192646A patent/CA3192646A1/en active Pending
- 2021-08-27 EP EP21862798.2A patent/EP4204555A4/en active Pending
- 2021-08-27 IL IL300671A patent/IL300671A/en unknown
- 2021-08-27 CN CN202180052964.9A patent/CN116075589A/zh active Pending
- 2021-08-27 US US18/023,060 patent/US20230321144A1/en active Pending
- 2021-08-27 AU AU2021331368A patent/AU2021331368A1/en active Pending
- 2021-08-27 WO PCT/US2021/047889 patent/WO2022047119A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10918738B2 (en) | Method of treating type I diabetes using an AAV vector encoding uracortin 2 | |
| JP5546453B2 (ja) | 脂肪肝疾患の治療におけるインターロイキン−22の使用 | |
| EP2142206B1 (en) | SDF-1 for use in the treatment of ischemic peripheral vascular disorders | |
| US6383785B1 (en) | Self-enhancing, pharmacologically controllable expression systems | |
| US20040161412A1 (en) | Cell-based VEGF delivery | |
| JP2002502608A (ja) | 血管新生促進因子である血管内皮細胞成長因子:vegfの変異体 | |
| JP2016019524A (ja) | ハイブリッドユビキチンプロモーターを含む発現ベクター | |
| JP2025121920A (ja) | 完全ヒト翻訳後修飾抗体による治療剤 | |
| JPH04502406A (ja) | ヒトdnアーゼ | |
| WO2015150914A2 (en) | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure | |
| JP2002540175A (ja) | 糖尿病及び肥満症の経口遺伝子治療 | |
| US20070020237A1 (en) | Glucose inducible insulin expression and methods of treating diabetes | |
| JP5269411B2 (ja) | 幹細胞をホーミングさせるためのccrリガンド | |
| JP2022513379A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2022186282A5 (cg-RX-API-DMAC7.html) | ||
| WO2024213660A1 (en) | Inflammation-inducible promoters | |
| US20240307556A1 (en) | Compositions and methods for reverse gene therapy | |
| MXPA04007934A (es) | Microorganismo envuelto. | |
| De Young et al. | 186 Modulation of vascular cell plasminogen activation by gene transfer In Vitro | |
| Ke et al. | 185 Rapid and efficient site-directed mutagenesis by single-tube ‘megaprimer’PCR method | |
| Simon et al. | 187 Adenovirus-mediated transfer of urokinase-type plasminogen activator genes to the lungs of mice upregulates plasminogen activator activity | |
| Cyclohydrolase et al. | 1111. Prolonged T 1. Prolonged T 1. Prolonged Transgene Expression in the ransgene Expression in the ransgene Expression in the Arterial Wall Using a Helper-Dependent all Using a Helper-Dependent all Using a Helper-Dependent Adenoviral V Adenoviral V Adenoviral Vector | |
| JPH03123735A (ja) | 悪性腫瘍治療剤 |